| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000737 | Dna catabolic process, endonucleolytic | Increases phenotype | PMID:25855085 |
| GO:0002263 | Cell activation involved in immune response | Increases phenotype | PMID:30685357 |
| GO:0002513 | Tolerance induction to self antigen | Decreases phenotype | PMID:33007382 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:26095957 |
| GO:0002524 | Hypersensitivity | Affects phenotype | PMID:35763063 |
| GO:0002885 | Positive regulation of hypersensitivity | Increases phenotype | PMID:30685357 |
| GO:0003094 | Glomerular filtration | Decreases phenotype | PMID:32763311 |
| GO:0003870 | 5-aminolevulinate synthase activity | Increases phenotype | PMID:6710543 |
| GO:0004364 | Glutathione transferase activity | Increases phenotype | PMID:30468822 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:25855085 |
| GO:0004697 | Protein kinase c activity | Increases phenotype | PMID:25855085 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:25855085 |
| GO:0006094 | Gluconeogenesis | Decreases phenotype | PMID:4344008 |
| GO:0006304 | Dna modification | Increases phenotype | PMID:30468822 |
| GO:0006497 | Protein lipidation | Increases phenotype | PMID:36849104 |
| GO:0006525 | Arginine metabolic process | Affects phenotype | PMID:35301063 |
| GO:0006603 | Phosphocreatine metabolic process | Affects phenotype | PMID:35301063 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:25855085 |
| GO:0006809 | Nitric oxide biosynthetic process | Decreases phenotype | PMID:31068537 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:25855085 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:25855085 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:33930529 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:23559643 |
| GO:0008152 | Metabolic process | Affects phenotype | PMID:23575800 |
| GO:0008219 | Cell death | Increases phenotype | PMID:26343699; PMID:31618666 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:26095957; PMID:34896440 |
| GO:0008284 | Positive regulation of cell population proliferation | Affects phenotype | PMID:23559643; PMID:28013219 |
| GO:0010468 | Regulation of gene expression | Affects phenotype | PMID:38518092 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:31068537; PMID:33636387 |
| GO:0016064 | Immunoglobulin mediated immune response | Affects phenotype | PMID:33007382 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:33007382; PMID:33636387; PMID:33930529 |
| GO:0019521 | D-gluconate metabolic process | Affects phenotype | PMID:35301063 |
| GO:0030388 | Fructose 1,6-bisphosphate metabolic process | Affects phenotype | PMID:35301063 |
| GO:0031345 | Negative regulation of cell projection organization | Increases phenotype | PMID:33132242 |
| GO:0031987 | Locomotion involved in locomotory behavior | Decreases phenotype | PMID:33636387 |
| GO:0032740 | Positive regulation of interleukin-17 production | Affects phenotype | PMID:22490199 |
| GO:0032755 | Positive regulation of interleukin-6 production | Affects phenotype | PMID:22490199 |
| GO:0035358 | Regulation of peroxisome proliferator activated receptor signaling pathway | Affects phenotype | PMID:23575800 |
| GO:0035696 | Monocyte extravasation | Increases phenotype | PMID:38485042 |
| GO:0035743 | Cd4-positive, alpha-beta t cell cytokine production | Affects phenotype | PMID:28369519 |
| GO:0036211 | Protein modification process | Increases phenotype | PMID:33007382 |
| GO:0044027 | Hypermethylation of cpg island | Increases phenotype | PMID:27553676 |
| GO:0044030 | Regulation of dna methylation | Affects phenotype | PMID:38518092 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:25855085; PMID:33387578 |
| GO:0044319 | Wound healing, spreading of cells | Increases phenotype | PMID:34233590 |
| GO:0045625 | Regulation of t-helper 1 cell differentiation | Affects phenotype | PMID:38518092 |
| GO:0045786 | Negative regulation of cell cycle | Increases phenotype | PMID:25855085 |
| GO:0045917 | Positive regulation of complement activation | Increases phenotype | PMID:32763311 |
| GO:0045922 | Negative regulation of fatty acid metabolic process | Affects phenotype | PMID:23575800 |
| GO:0046031 | Adp metabolic process | Affects phenotype | PMID:35301063 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:35301063 |
| GO:0046039 | Gtp metabolic process | Affects phenotype | PMID:35301063 |
| GO:0046415 | Urate metabolic process | Decreases phenotype | PMID:33132242 |
| GO:0046449 | Creatinine metabolic process | Decreases phenotype | PMID:33132242 |
| GO:0046470 | Phosphatidylcholine metabolic process | Affects phenotype | PMID:23575800 |
| GO:0046710 | Gdp metabolic process | Affects phenotype | PMID:35301063 |
| GO:0046960 | Sensitization | Increases phenotype | PMID:31068537 |
| GO:0047804 | Cysteine-s-conjugate beta-lyase activity | Decreases phenotype | PMID:33599830 |
| GO:0050729 | Positive regulation of inflammatory response | Increases phenotype | PMID:38485042 |
| GO:0051767 | Nitric-oxide synthase biosynthetic process | Decreases phenotype | PMID:31068537 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:25855085 |
| GO:0051899 | Membrane depolarization | Increases phenotype | PMID:25855085 |
| GO:0055091 | Phospholipid homeostasis | Affects phenotype | PMID:23575800 |
| GO:0060326 | Cell chemotaxis | Increases phenotype | PMID:34233590 |
| GO:0061744 | Motor behavior | Decreases phenotype | PMID:37669148 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:36849104 |
| GO:0070997 | Neuron death | Increases phenotype | PMID:33636387 |
| GO:0072387 | Flavin adenine dinucleotide metabolic process | Affects phenotype | PMID:35301063 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:25855085; PMID:29722447 |
| GO:0072672 | Neutrophil extravasation | Increases phenotype | PMID:38485042 |
| GO:0072676 | Lymphocyte migration | Increases phenotype | PMID:33930529 |
| GO:0090659 | Walking behavior | Decreases phenotype | PMID:37669148 |
| GO:1900745 | Positive regulation of p38mapk cascade | Increases phenotype | PMID:30685357; PMID:32763311 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:37669148 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:23559643 |
| GO:1903980 | Positive regulation of microglial cell activation | Increases phenotype | PMID:37669148 |
| GO:2000321 | Positive regulation of t-helper 17 cell differentiation | Affects phenotype | PMID:22490199 |
| GO:2001022 | Positive regulation of response to dna damage stimulus | Increases phenotype | PMID:29722447 |
| GO:2001057 | Reactive nitrogen species metabolic process | Affects phenotype | PMID:25855085 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.